1. Home
  2. GLPG vs VBTX Comparison

GLPG vs VBTX Comparison

Compare GLPG & VBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLPG
  • VBTX
  • Stock Information
  • Founded
  • GLPG 1999
  • VBTX 2009
  • Country
  • GLPG Belgium
  • VBTX United States
  • Employees
  • GLPG N/A
  • VBTX N/A
  • Industry
  • GLPG Biotechnology: Pharmaceutical Preparations
  • VBTX Major Banks
  • Sector
  • GLPG Health Care
  • VBTX Finance
  • Exchange
  • GLPG Nasdaq
  • VBTX Nasdaq
  • Market Cap
  • GLPG 2.1B
  • VBTX 1.9B
  • IPO Year
  • GLPG 2005
  • VBTX 2014
  • Fundamental
  • Price
  • GLPG $32.02
  • VBTX $34.40
  • Analyst Decision
  • GLPG Sell
  • VBTX Buy
  • Analyst Count
  • GLPG 4
  • VBTX 6
  • Target Price
  • GLPG $25.33
  • VBTX $33.00
  • AVG Volume (30 Days)
  • GLPG 198.2K
  • VBTX 817.4K
  • Earning Date
  • GLPG 10-29-2025
  • VBTX 10-21-2025
  • Dividend Yield
  • GLPG N/A
  • VBTX 2.56%
  • EPS Growth
  • GLPG N/A
  • VBTX 31.14
  • EPS
  • GLPG N/A
  • VBTX 2.10
  • Revenue
  • GLPG $323,674,692.00
  • VBTX $424,480,000.00
  • Revenue This Year
  • GLPG N/A
  • VBTX $12.36
  • Revenue Next Year
  • GLPG N/A
  • VBTX $4.80
  • P/E Ratio
  • GLPG N/A
  • VBTX $16.38
  • Revenue Growth
  • GLPG 5.43
  • VBTX 16.89
  • 52 Week Low
  • GLPG $22.36
  • VBTX $20.37
  • 52 Week High
  • GLPG $33.86
  • VBTX $34.96
  • Technical
  • Relative Strength Index (RSI)
  • GLPG 49.28
  • VBTX 64.66
  • Support Level
  • GLPG $30.88
  • VBTX $33.99
  • Resistance Level
  • GLPG $33.63
  • VBTX $34.64
  • Average True Range (ATR)
  • GLPG 0.69
  • VBTX 0.58
  • MACD
  • GLPG -0.02
  • VBTX -0.08
  • Stochastic Oscillator
  • GLPG 41.45
  • VBTX 68.72

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About VBTX Veritex Holdings Inc.

Veritex Holdings Inc is engaged in the provision of commercial banking products and services to small to medium-sized businesses and professionals. The bank provides a range of banking services to individual and corporate customers, which include commercial and retail lending, and the acceptance of checking and savings deposits. It offers a suite of online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, as well as automated teller machines, and banking by telephone, mail and personal appointment. The company's primary sources of revenue are derived from interest and dividends earned on loans, debt and equity securities and other financial instruments.

Share on Social Networks: